公开(公告)号：SI1268429T1

公开(公告)日：2004-12-31

申请号：SI200130167

申请日：2001-03-06

Applicant: SERVIER LAB

Inventor： CASARA PATRICK ,  PERRON-SIERRA FRANCOISE ,  ATASSI GHANEM ,  TUCKER GORDON ,  SAINT-DIZIER DOMINIQUE

IPC: A61K31/4164 ,  A61K31/4168 ,  A61K31/417 ,  A61K31/4184 ,  A61K31/426 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/505 ,  A61K31/55 ,  A61P9/00 ,  C07D233/24 ,  A61P19/10 ,  A61P27/02 ,  A61P29/00 ,  A61P33/14 ,  A61P35/00 ,  A61P43/00 ,  C07D213/36 ,  C07D213/74 ,  C07D223/04 ,  C07D223/12 ,  C07D233/48 ,  C07D233/54 ,  C07D235/10 ,  C07D235/14 ,  C07D235/30 ,  C07D239/14 ,  C07D277/18 ,  C07D277/20 ,  C07D277/42 ,  C07D401/12 ,  C07D403/12 ,  C07D471/04

Abstract: Compounds of formula (1):wherein:G represents an optionally substituted phenyl or optionally substituted heterocycle, G1 and G2 being N or C,T1 represents -CH2-CH2-, -CH=CH- or =CH-CH2-, and T2 is a bond, or T1 represents -CH2- or =CH- and T2 is -CH2-, =CH-,R5 represents -(CH2)m-COOR6,R6 and R6' represent hydrogen, alkyl, optionally substituted aryl or optionally substituted arylalkyl,A represents -CO-, -CH2-, =CH- or -CH= and W represents -CH-, =C- or -C=, or A represents -CO- or -CH2- and W represents N,X represents -CO-X1-, -CO-NR6-X1-, -NR6-CO-X1-, -O-X1-, -SO2-NR6-X1- or -S(O)n-X1-,Y represents -Y1-, -Y2-Y1- or -Y1-Y2-Y1-, Y1 being an alkylene, alkenylene or alkynylene, and Y2 being an arylene, heteroarylene, cycloalkylene or heterocycloalkylene,Z represents -Z1-, -Z10-NR6-, and -Z10-NR6-CO-, Z1 being a heteroaryl, heterocycloalkyl, heteroarylalkyl, heterocycloalkylalkyl, fused arylheteroaryl, fused arylheterocycloalkyl, fused heteroarylheterocycloalkyl, fused heterocycloalkylheteroaryl or fused heteroarylheteroaryl, each of which is optionally substituted, or a group,Z2-NR6 or Z2-NR6-CO, Z2 being a group Z1, alkyl or heteroalkyl, andZ10 represents Z1 or an alkyl,its enantiomers, diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base,and medicinal products containing the same which are useful as vitronectin receptor antagonists.

公开(公告)号：AU9337401A

公开(公告)日：2001-10-30

申请号：AU9337401

申请日：2001-03-06

Applicant: SERVIER LAB

Inventor： CASARA PATRICK ,  PERRON-SIERRA FRANCOISE ,  ATASSI GHANEM ,  TUCKER GORDON ,  SAINT-DIZIER DOMINIQUE

IPC: C07D233/24 ,  A61K31/4164 ,  A61K31/4168 ,  A61K31/417 ,  A61K31/4184 ,  A61K31/426 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/505 ,  A61K31/55 ,  A61P9/00 ,  A61P19/10 ,  A61P27/02 ,  A61P29/00 ,  A61P33/14 ,  A61P35/00 ,  A61P43/00 ,  C07D213/36 ,  C07D213/74 ,  C07D223/04 ,  C07D223/12 ,  C07D233/48 ,  C07D233/54 ,  C07D235/10 ,  C07D235/14 ,  C07D235/30 ,  C07D239/14 ,  C07D277/18 ,  C07D277/20 ,  C07D277/42 ,  C07D401/12 ,  C07D403/12 ,  C07D471/04

Abstract: Compounds of formula (1):wherein:G represents an optionally substituted phenyl or optionally substituted heterocycle, G1 and G2 being N or C,T1 represents -CH2-CH2-, -CH=CH- or =CH-CH2-, and T2 is a bond, or T1 represents -CH2- or =CH- and T2 is -CH2-, =CH-,R5 represents -(CH2)m-COOR6,R6 and R6' represent hydrogen, alkyl, optionally substituted aryl or optionally substituted arylalkyl,A represents -CO-, -CH2-, =CH- or -CH= and W represents -CH-, =C- or -C=, or A represents -CO- or -CH2- and W represents N,X represents -CO-X1-, -CO-NR6-X1-, -NR6-CO-X1-, -O-X1-, -SO2-NR6-X1- or -S(O)n-X1-,Y represents -Y1-, -Y2-Y1- or -Y1-Y2-Y1-, Y1 being an alkylene, alkenylene or alkynylene, and Y2 being an arylene, heteroarylene, cycloalkylene or heterocycloalkylene,Z represents -Z1-, -Z10-NR6-, and -Z10-NR6-CO-, Z1 being a heteroaryl, heterocycloalkyl, heteroarylalkyl, heterocycloalkylalkyl, fused arylheteroaryl, fused arylheterocycloalkyl, fused heteroarylheterocycloalkyl, fused heterocycloalkylheteroaryl or fused heteroarylheteroaryl, each of which is optionally substituted, or a group,Z2-NR6 or Z2-NR6-CO, Z2 being a group Z1, alkyl or heteroalkyl, andZ10 represents Z1 or an alkyl,its enantiomers, diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base,and medicinal products containing the same which are useful as vitronectin receptor antagonists.

公开(公告)号：DE60105001T2

公开(公告)日：2005-08-18

申请号：DE60105001

申请日：2001-03-06

Applicant: SERVIER LAB

Inventor： CASARA PATRICK ,  PERRON-SIERRA FRANCOISE ,  ATASSI GHANEM ,  TUCKER GORDON ,  SAINT-DIZIER DOMINIQUE

IPC: C07D233/24 ,  A61K31/4164 ,  A61K31/4168 ,  A61K31/417 ,  A61K31/4184 ,  A61K31/426 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/505 ,  A61K31/55 ,  A61P9/00 ,  A61P19/10 ,  A61P27/02 ,  A61P29/00 ,  A61P33/14 ,  A61P35/00 ,  A61P43/00 ,  C07D213/36 ,  C07D213/74 ,  C07D223/04 ,  C07D223/12 ,  C07D233/48 ,  C07D233/54 ,  C07D235/10 ,  C07D235/14 ,  C07D235/30 ,  C07D239/14 ,  C07D277/18 ,  C07D277/20 ,  C07D277/42 ,  C07D401/12 ,  C07D403/12 ,  C07D471/04

Abstract: Compounds of formula (1):wherein:G represents an optionally substituted phenyl or optionally substituted heterocycle, G1 and G2 being N or C,T1 represents -CH2-CH2-, -CH=CH- or =CH-CH2-, and T2 is a bond, or T1 represents -CH2- or =CH- and T2 is -CH2-, =CH-,R5 represents -(CH2)m-COOR6,R6 and R6' represent hydrogen, alkyl, optionally substituted aryl or optionally substituted arylalkyl,A represents -CO-, -CH2-, =CH- or -CH= and W represents -CH-, =C- or -C=, or A represents -CO- or -CH2- and W represents N,X represents -CO-X1-, -CO-NR6-X1-, -NR6-CO-X1-, -O-X1-, -SO2-NR6-X1- or -S(O)n-X1-,Y represents -Y1-, -Y2-Y1- or -Y1-Y2-Y1-, Y1 being an alkylene, alkenylene or alkynylene, and Y2 being an arylene, heteroarylene, cycloalkylene or heterocycloalkylene,Z represents -Z1-, -Z10-NR6-, and -Z10-NR6-CO-, Z1 being a heteroaryl, heterocycloalkyl, heteroarylalkyl, heterocycloalkylalkyl, fused arylheteroaryl, fused arylheterocycloalkyl, fused heteroarylheterocycloalkyl, fused heterocycloalkylheteroaryl or fused heteroarylheteroaryl, each of which is optionally substituted, or a group,Z2-NR6 or Z2-NR6-CO, Z2 being a group Z1, alkyl or heteroalkyl, andZ10 represents Z1 or an alkyl,its enantiomers, diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base,and medicinal products containing the same which are useful as vitronectin receptor antagonists.

公开(公告)号：AR029485A1

公开(公告)日：2003-07-02

申请号：ARP010101058

申请日：2001-03-07

Applicant: SERVIER LAB

Inventor： CASARA PATRICK ,  PERRON-SIERRA FRANCOISE ,  ATASSI GHANEM ,  TUCKER GORDON ,  SAINT-DIZIER DOMINIQUE

IPC: C07D233/24 ,  A61K31/4164 ,  A61K31/4168 ,  A61K31/417 ,  A61K31/4184 ,  A61K31/426 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/505 ,  A61K31/55 ,  A61P9/00 ,  A61P19/10 ,  A61P27/02 ,  A61P29/00 ,  A61P33/14 ,  A61P35/00 ,  A61P43/00 ,  C07D213/36 ,  C07D213/74 ,  C07D223/04 ,  C07D223/12 ,  C07D233/48 ,  C07D233/54 ,  C07D235/10 ,  C07D235/14 ,  C07D235/30 ,  C07D239/14 ,  C07D277/18 ,  C07D277/20 ,  C07D277/42 ,  C07D401/12 ,  C07D403/12 ,  C07D471/04 ,  A61K31/402

Abstract: Compuestos de formula (1) en la cual: G representa un grupo fenilo o un grupo heterocíclico aromático o parcialmente insaturado, de 6 eslabones, que contiene de 1 a 2 heteroátomos elegidos entre nitrogeno y oxígeno, no substituido o substituido por R1, R2, R3 y/o R4; G1 y G2 representan independientemente, un átomo de carbono o de nitrogeno; -T1- representa un grupo elegido entre -CH2-CH2-, -CH=CH-, =CH-CH2-, y en ese caso, -T2- representa un enlace, o bien -T1- representa un grupo elegido entre -CH2- y -CH- y en ese caso -T2- representa un grupo -CH2-, =CH-, (a) o (b); R1, R2, R3 y R4, representan independientemente, un átomo de halogeno, un grupo alquilo, perhalogenoalquilo, ciano, nitro, OR7, NR6R6', COOR6, CONR6R6', COR6, S(O)nR6, siendo n igual a 0, 1 o 2; R5 representa un grupo -(CH2)m-COOR6; R6 y R6' representan independientemente, un átomo de hidrogeno, un grupo alquilo, arilo eventualmente substituido o arilalquilo eventualmente substituido; R7 representa un átomo de hidrogeno o un grupo alquilo; -W- representa un grupo -CH-, =C-, o -C= y -A- representa un grupo -CO-, -CH2-, =CH- o -CH=, o bien -W- representa un átomo de nitrogeno y -A- representa un grupo -CO- o -CH2-; -X- representa un grupo elegido entre -CO-X1-, -CO-NR6-X1-, -NR6-CO-X1-, -O-X1-, -SO2-NR6-X1-, y -S(O)n-X1-, en los cuales n está comprendido inclusivamente entre 0 y 2, y X1 representa un grupo alquileno; -Y- representa un grupo elegido entre -Y1-, -Y2-Y1- y -Y1-Y2-Y1-, en los cuales Y1 representa un grupo alquileno, alquenileno o alquinileno, e Y2 representa un grupo arileno, heteroarileno, cicloalquileno o heterocicloalquileno; Z- representa un grupo elegido entre Z1-, Z10-NR6-, y Z10-NR6-CO- en los cuales Z10 representa un grupo alquilo o Z1, y Z1 representa un grupo elegido entre Z2-, Z20-NR6-, Z20-NR6-CO-, o (c), en los cuales Z20 representa un grupo alquilo, heteroalquilo o Z2, y Z2 representa un grupo heteroarilo eventualmente substituido, heterocicloalquilo eventualmente substituido, heteroarilalquilo eventualmente substituido, heterocicloalquilalquilo eventualmente substituido, arilheteroarilo fusionado eventualmente substituido, arilheterocicloalquilo fusionado eventualmente substituido, heterocicloalquilheteroarilo fusionado eventualmente substituido, heteroarilheteroarilo fusionado eventualmente substituido, o cicloalquilheterocicloalquilo fusionado; y m es un entero comprendido en forma incluida entre 1 y 6. Estos compuestos son utiles en la preparacion de medicamentos.

公开(公告)号：CZ20022992A3

公开(公告)日：2003-02-12

申请号：CZ20022992

申请日：2001-03-06

Applicant: SERVIER LAB

Inventor： CASARA PATRICK ,  PERRON-SIERRA FRANCOISE ,  ATASSI GHANEM ,  TUCKER GORDON ,  SAINT-DIZIER DOMINIQUE

IPC: C07D233/24 ,  A61K31/4164 ,  A61K31/4168 ,  A61K31/417 ,  A61K31/4184 ,  A61K31/426 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/505 ,  A61K31/55 ,  A61P9/00 ,  A61P19/10 ,  A61P27/02 ,  A61P29/00 ,  A61P33/14 ,  A61P35/00 ,  A61P43/00 ,  C07D213/36 ,  C07D213/74 ,  C07D223/04 ,  C07D223/12 ,  C07D233/48 ,  C07D233/54 ,  C07D235/10 ,  C07D235/14 ,  C07D235/30 ,  C07D239/14 ,  C07D277/18 ,  C07D277/20 ,  C07D277/42 ,  C07D401/12 ,  C07D403/12 ,  C07D471/04

Abstract: Compounds of formula (1):wherein:G represents an optionally substituted phenyl or optionally substituted heterocycle, G1 and G2 being N or C,T1 represents -CH2-CH2-, -CH=CH- or =CH-CH2-, and T2 is a bond, or T1 represents -CH2- or =CH- and T2 is -CH2-, =CH-,R5 represents -(CH2)m-COOR6,R6 and R6' represent hydrogen, alkyl, optionally substituted aryl or optionally substituted arylalkyl,A represents -CO-, -CH2-, =CH- or -CH= and W represents -CH-, =C- or -C=, or A represents -CO- or -CH2- and W represents N,X represents -CO-X1-, -CO-NR6-X1-, -NR6-CO-X1-, -O-X1-, -SO2-NR6-X1- or -S(O)n-X1-,Y represents -Y1-, -Y2-Y1- or -Y1-Y2-Y1-, Y1 being an alkylene, alkenylene or alkynylene, and Y2 being an arylene, heteroarylene, cycloalkylene or heterocycloalkylene,Z represents -Z1-, -Z10-NR6-, and -Z10-NR6-CO-, Z1 being a heteroaryl, heterocycloalkyl, heteroarylalkyl, heterocycloalkylalkyl, fused arylheteroaryl, fused arylheterocycloalkyl, fused heteroarylheterocycloalkyl, fused heterocycloalkylheteroaryl or fused heteroarylheteroaryl, each of which is optionally substituted, or a group,Z2-NR6 or Z2-NR6-CO, Z2 being a group Z1, alkyl or heteroalkyl, andZ10 represents Z1 or an alkyl,its enantiomers, diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base,and medicinal products containing the same which are useful as vitronectin receptor antagonists.

公开(公告)号：BR0108998A

公开(公告)日：2002-12-17

申请号：BR0108998

申请日：2001-03-06

Applicant: SERVIER LAB

Inventor： CASARA PATRICK ,  PERRON-SIERRA FRANCOISE ,  ATASSI GHANEM ,  TUCKER GORDON ,  SAINT-DIZIER DOMINIQUE

IPC: C07D233/24 ,  A61K31/4164 ,  A61K31/4168 ,  A61K31/417 ,  A61K31/4184 ,  A61K31/426 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/505 ,  A61K31/55 ,  A61P9/00 ,  A61P19/10 ,  A61P27/02 ,  A61P29/00 ,  A61P33/14 ,  A61P35/00 ,  A61P43/00 ,  C07D213/36 ,  C07D213/74 ,  C07D223/04 ,  C07D223/12 ,  C07D233/48 ,  C07D233/54 ,  C07D235/10 ,  C07D235/14 ,  C07D235/30 ,  C07D239/14 ,  C07D277/18 ,  C07D277/20 ,  C07D277/42 ,  C07D401/12 ,  C07D403/12 ,  C07D471/04

Abstract: Compounds of formula (1):wherein:G represents an optionally substituted phenyl or optionally substituted heterocycle, G1 and G2 being N or C,T1 represents -CH2-CH2-, -CH=CH- or =CH-CH2-, and T2 is a bond, or T1 represents -CH2- or =CH- and T2 is -CH2-, =CH-,R5 represents -(CH2)m-COOR6,R6 and R6' represent hydrogen, alkyl, optionally substituted aryl or optionally substituted arylalkyl,A represents -CO-, -CH2-, =CH- or -CH= and W represents -CH-, =C- or -C=, or A represents -CO- or -CH2- and W represents N,X represents -CO-X1-, -CO-NR6-X1-, -NR6-CO-X1-, -O-X1-, -SO2-NR6-X1- or -S(O)n-X1-,Y represents -Y1-, -Y2-Y1- or -Y1-Y2-Y1-, Y1 being an alkylene, alkenylene or alkynylene, and Y2 being an arylene, heteroarylene, cycloalkylene or heterocycloalkylene,Z represents -Z1-, -Z10-NR6-, and -Z10-NR6-CO-, Z1 being a heteroaryl, heterocycloalkyl, heteroarylalkyl, heterocycloalkylalkyl, fused arylheteroaryl, fused arylheterocycloalkyl, fused heteroarylheterocycloalkyl, fused heterocycloalkylheteroaryl or fused heteroarylheteroaryl, each of which is optionally substituted, or a group,Z2-NR6 or Z2-NR6-CO, Z2 being a group Z1, alkyl or heteroalkyl, andZ10 represents Z1 or an alkyl,its enantiomers, diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base,and medicinal products containing the same which are useful as vitronectin receptor antagonists.

公开(公告)号：NO20024275L

公开(公告)日：2002-09-06

申请号：NO20024275

申请日：2002-09-06

Applicant: SERVIER LAB

Inventor： CASARA PATRICK ,  PERRON-SIERRA FRANCOISE ,  ATASSI GHANEM ,  TUCKER GORDON ,  SAINT-DIZIER DOMINIQUE

IPC: A61K31/4164 ,  C07D233/24 ,  A61K31/4168 ,  A61K31/417 ,  A61K31/4184 ,  A61K31/426 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/505 ,  A61K31/55 ,  A61P9/00 ,  A61P19/10 ,  A61P27/02 ,  A61P29/00 ,  A61P33/14 ,  A61P35/00 ,  A61P43/00 ,  C07D213/36 ,  C07D213/74 ,  C07D223/04 ,  C07D223/12 ,  C07D233/48 ,  C07D233/54 ,  C07D235/10 ,  C07D235/14 ,  C07D235/30 ,  C07D239/14 ,  C07D277/18 ,  C07D277/20 ,  C07D277/42 ,  C07D401/12 ,  C07D403/12 ,  C07D471/04

Abstract: Compounds of formula (1):wherein:G represents an optionally substituted phenyl or optionally substituted heterocycle, G1 and G2 being N or C,T1 represents -CH2-CH2-, -CH=CH- or =CH-CH2-, and T2 is a bond, or T1 represents -CH2- or =CH- and T2 is -CH2-, =CH-,R5 represents -(CH2)m-COOR6,R6 and R6' represent hydrogen, alkyl, optionally substituted aryl or optionally substituted arylalkyl,A represents -CO-, -CH2-, =CH- or -CH= and W represents -CH-, =C- or -C=, or A represents -CO- or -CH2- and W represents N,X represents -CO-X1-, -CO-NR6-X1-, -NR6-CO-X1-, -O-X1-, -SO2-NR6-X1- or -S(O)n-X1-,Y represents -Y1-, -Y2-Y1- or -Y1-Y2-Y1-, Y1 being an alkylene, alkenylene or alkynylene, and Y2 being an arylene, heteroarylene, cycloalkylene or heterocycloalkylene,Z represents -Z1-, -Z10-NR6-, and -Z10-NR6-CO-, Z1 being a heteroaryl, heterocycloalkyl, heteroarylalkyl, heterocycloalkylalkyl, fused arylheteroaryl, fused arylheterocycloalkyl, fused heteroarylheterocycloalkyl, fused heterocycloalkylheteroaryl or fused heteroarylheteroaryl, each of which is optionally substituted, or a group,Z2-NR6 or Z2-NR6-CO, Z2 being a group Z1, alkyl or heteroalkyl, andZ10 represents Z1 or an alkyl,its enantiomers, diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base,and medicinal products containing the same which are useful as vitronectin receptor antagonists.

公开(公告)号：CA2402686C

公开(公告)日：2008-02-05

申请号：CA2402686

申请日：2001-03-06

Applicant: SERVIER LAB

Inventor： CASARA PATRICK ,  TUCKER GORDON ,  ATASSI GHANEM ,  PERRON-SIERRA FRANCOISE ,  SAINT-DIZIER DOMINIQUE

IPC: C07D213/74 ,  C07D233/24 ,  A61K31/4164 ,  A61K31/4168 ,  A61K31/417 ,  A61K31/4184 ,  A61K31/426 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/505 ,  A61K31/55 ,  A61P9/00 ,  A61P19/10 ,  A61P27/02 ,  A61P29/00 ,  A61P33/14 ,  A61P35/00 ,  A61P43/00 ,  C07D213/36 ,  C07D223/04 ,  C07D223/12 ,  C07D233/48 ,  C07D233/54 ,  C07D235/10 ,  C07D235/14 ,  C07D235/30 ,  C07D239/14 ,  C07D277/18 ,  C07D277/20 ,  C07D277/42 ,  C07D401/12 ,  C07D403/12 ,  C07D471/04

Abstract: L'invention concerne de nouveaux composés répondant à la formule (I) : dans laquelle G représente un groupement phényle; G1 et G2 représentent un atome de carbone; T1 représente un groupement -CH2-CH2-, -CH=CH- ou =CH-CH2-, et -T2- représen te une liaison, R5 représente un groupement -(CH2)m-COOR6 dans lequel m est un enti er compris entre 1 et 6 inclusivement; R6 représentent un atome d'hydrogène ou un groupement alkyle, aryle ou arylalkyle; W représente un groupement -CH-, =C- ou -C= et A représente un groupement -CH2- ou =CH-; X représente un groupement choisi parmi -CO-X1-, - CO- NR6- X1-, -NR6-CO-X1-, -O-X1-, -SO2-NR6-X1- et -S(O)n-X1-, dans lesquels n est compris entre 0 et 2 inclusivement, et X1 représente un groupement alkylène; Y représente un groupement choisi parmi -Y1-, -Y2-Y1- et -Y1-Y2-Y1-, dans lesquels Y1 représente un groupement alkylène, alkénylène ou alkynylène, et Y2 représente un groupemen t arylène, hétéroarylène, cycloalkylène ou hétérocycloalkylène; Z représente un groupement choisi parmi Z1-, Z10-NR6- et Z10-NR6-CO-, dans lesquels Z10 représente un groupeme nt alkyle ou Z1, et Z1 représente un groupement choisi parmi Z2, Z2O-(C=NR6)-, Z20-NR6- e t Z20-NR6- CO-, dans lesquels Z20 représente un groupement alkyle, hétéroalkyle ou Z2, et Z2 représente ungroupement hétéroaryle, hétérocycloalkyle, hétéroarylalkyle, hétérocycloalkylalkyle, arylhétéroaryle fusionné, arylhétérocycloalkyle fusionné, hétéroarylhétérocycloalkyle fusionné, hétérocycloalkyl-hétéroaryle fusionné, hétéroarylhétéroaryle fusionné ou cycloalkylhétérocycloalkyle fusionné. L'invention vise également les énantiomères et diastéréoisomères des composés de formule (I), ainsi que leurs sels d'addition à un acide ou à une base pharmaceutiquement acceptable . Les composés selon l'invention sont utiles à titre de médicaments pour le traitement des maladies cardiovasculaires, des maladies inflammatoires, du cancer, de l'ostéoporose, de l'arthrite rhumatoïde, du psoriasis, des rétinopathies et des cancers.

公开(公告)号：AU2001293374B2

公开(公告)日：2005-02-17

申请号：AU2001293374

申请日：2001-03-06

Applicant: SERVIER LAB

Inventor： CASARA PATRICK ,  PERRON-SIERRA FRANCOISE ,  ATASSI GHANEM ,  TUCKER GORDON ,  SAINT-DIZIER DOMINIQUE

IPC: C07D233/24 ,  A61K31/4164 ,  A61K31/4168 ,  A61K31/417 ,  A61K31/4184 ,  A61K31/426 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/505 ,  A61K31/55 ,  A61P9/00 ,  A61P19/10 ,  A61P27/02 ,  A61P29/00 ,  A61P33/14 ,  A61P35/00 ,  A61P43/00 ,  C07D213/36 ,  C07D213/74 ,  C07D223/04 ,  C07D223/12 ,  C07D233/48 ,  C07D233/54 ,  C07D235/10 ,  C07D235/14 ,  C07D235/30 ,  C07D239/14 ,  C07D277/18 ,  C07D277/20 ,  C07D277/42 ,  C07D401/12 ,  C07D403/12 ,  C07D471/04 ,  A61P009/00 ,  A61K031/55 ,  A61K031/44 ,  A61K031/4184 ,  A61K031/4164

Abstract: Compounds of formula (1):wherein:G represents an optionally substituted phenyl or optionally substituted heterocycle, G1 and G2 being N or C,T1 represents -CH2-CH2-, -CH=CH- or =CH-CH2-, and T2 is a bond, or T1 represents -CH2- or =CH- and T2 is -CH2-, =CH-,R5 represents -(CH2)m-COOR6,R6 and R6' represent hydrogen, alkyl, optionally substituted aryl or optionally substituted arylalkyl,A represents -CO-, -CH2-, =CH- or -CH= and W represents -CH-, =C- or -C=, or A represents -CO- or -CH2- and W represents N,X represents -CO-X1-, -CO-NR6-X1-, -NR6-CO-X1-, -O-X1-, -SO2-NR6-X1- or -S(O)n-X1-,Y represents -Y1-, -Y2-Y1- or -Y1-Y2-Y1-, Y1 being an alkylene, alkenylene or alkynylene, and Y2 being an arylene, heteroarylene, cycloalkylene or heterocycloalkylene,Z represents -Z1-, -Z10-NR6-, and -Z10-NR6-CO-, Z1 being a heteroaryl, heterocycloalkyl, heteroarylalkyl, heterocycloalkylalkyl, fused arylheteroaryl, fused arylheterocycloalkyl, fused heteroarylheterocycloalkyl, fused heterocycloalkylheteroaryl or fused heteroarylheteroaryl, each of which is optionally substituted, or a group,Z2-NR6 or Z2-NR6-CO, Z2 being a group Z1, alkyl or heteroalkyl, andZ10 represents Z1 or an alkyl,its enantiomers, diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base,and medicinal products containing the same which are useful as vitronectin receptor antagonists.

公开(公告)号：NZ520805A

公开(公告)日：2004-12-24

申请号：NZ52080501

申请日：2001-03-06

Applicant: SERVIER LAB

Inventor： CASARA PATRICK ,  PERRON-SIERRA FRANCOISE ,  ATASSI GHANEM ,  TUCKER GORDON ,  SAINT-DIZIER DOMINIQUE

IPC: A61K31/4164 ,  A61K31/4168 ,  A61K31/417 ,  A61K31/4184 ,  A61K31/426 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/505 ,  A61K31/55 ,  A61P9/00 ,  C07D233/24 ,  A61P19/10 ,  A61P27/02 ,  A61P29/00 ,  A61P33/14 ,  A61P35/00 ,  A61P43/00 ,  C07D213/36 ,  C07D213/74 ,  C07D223/04 ,  C07D223/12 ,  C07D233/48 ,  C07D233/54 ,  C07D235/10 ,  C07D235/14 ,  C07D235/30 ,  C07D239/14 ,  C07D277/18 ,  C07D277/20 ,  C07D277/42 ,  C07D401/12 ,  C07D403/12 ,  C07D471/04

Abstract: A bicyclic compound of formula (I); the preparation thereof; and use of the compound as vitronectin receptor antagonists is disclosed, wherein the variables are as defined in the specification.